Savarino V, Tosetti C, Benedetto E, Compare D, Nardone G. Appropriateness in prescribing PPIs: a position paper of the Italian Society of Gastroenterology (SIGE) - Study section “Digestive Diseases in Primary Care”. Dig Liver Dis. 2018;50:894–902. https://doi.org/10.1016/j.dld.2018.07.004.

Savarino V, Dulbecco P, de Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19–24. https://doi.org/10.1016/j.ejim.2016.10.007.

Article  CAS  PubMed  Google Scholar 

Balivada V, Koraykar RM. A narrative review on rebound acid hypersecretion due to long-term use of proton pump inhibitors. Ann Natl Acad Med Sci. 2024;60:113–9.

Article  Google Scholar 

Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023;79:1159–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side effects of long-term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol. 2018;123:114–21.

Article  CAS  PubMed  Google Scholar 

Eusebi LH, Rabitti S, Artesiani ML, et al. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol. 2017;32:1295–302.

Article  PubMed  Google Scholar 

Šahinović I, Borzan V, Fijačko M, Šerić V. Proton pump inhibitor therapy causes increased chromogranine A concentration. 9 kongres hrvatskog društva za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM); 2018. p. S96–S7.

Ozsoy MS, Erol CI, Aydemir MA, et al. Gastroenteropancreatic neuroendocrine tumors: does tumor location affect prognosis? Arch Iran Med. 2025;28:29. https://doi.org/10.34172/AIM.33366.

Article  PubMed  PubMed Central  Google Scholar 

Frilling A, Åkerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM. Neuroendocrine tumor disease: an evolving landscape. Endocrine-related cancer. 2012;19:R163–85.

McClellan K, Chen EY, Kardosh A, Lopez CD, Del Rivero J, Mallak N, Rocha FG, Koethe Y, Pommier R, Mittra E, Pegna GJ. Therapy resistant gastroenteropancreatic neuroendocrine tumors. Cancers. 2022;14:4769.

Balachandran A, Fleming JB, Callender GG, Krishnan S, Yao JC. Chapter 13 - Pancreatic neuroendocrine tumors. In: Silverman PM, editor. Oncologic imaging: a multidisciplinary approach. Philadelphia: W.B. Saunders; 2012. p. 193–209.

Di Domenico A, Pipinikas CP, Maire RS, et al. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol. 2020. https://doi.org/10.1038/s42003-020-01479-y.

Simon T, Riemer P, Jarosch A, et al. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors. Genome Med. 2022. https://doi.org/10.1186/S13073-022-01018-W.

Xu Z, Wang L, Dai S, et al. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw Open. 2021;4:2124750. https://doi.org/10.1001/jamanetworkopen.2021.24750.

Article  Google Scholar 

Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54:iv1–6.

Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63–71.

Article  PubMed  Google Scholar 

Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59.

Article  PubMed  Google Scholar 

Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

Article  PubMed  Google Scholar 

Modlin IM, Champaneria MC, Chan AKC, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol. 2007;102:1464–73.

Article  PubMed  Google Scholar 

Liu M, Wei L, Liu W, et al. Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: a SEER database analysis, 1977–2016. frontiersin.org. 2023;13 https://doi.org/10.3389/FONC.2023.1079575/FULL

Kim BW, Lee BI, Kim HK, et al. Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin. Korean J Gastroenterol. 2009;53:84–9.

CAS  PubMed  Google Scholar 

Karnik NP, Yang Z, Kochman ML, et al. Sa1150 can long term use of proton pump inhibitors lead to gastric neuroendocrine tumor development? Gastroenterology. 2020;158:S-291.

Article  Google Scholar 

Gupta SR, Channen L, Habr F. S5192 Gastric neuroendocrine tumor induced by long-term PPI use. Am J Gastroenterol | ACG. 2024;119:S3251.

Trinh VQ, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology. 2020;77:865–76.

Article  PubMed  Google Scholar 

Tatsuguchi A, Hoshino S, Kawami N, et al. Sa1200–hypergastrinemia secondary to long-term proton pump inhibitor treatment does not cause neuroendocrine tumor in stomach. Gastroenterology. 2019;156:S-305.

Article  Google Scholar 

Patwardhan SS, Basil A, Meunier R, et al. Is long-term PPI use associated with the development of gastric neuroendocrine tumors?: 2549. Am J Gastroenterol. 2016;111:S1290.

Article  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535.

Article  PubMed  PubMed Central  Google Scholar 

Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc. 2005;19:1610–2. https://doi.org/10.1007/S00464-005-0232-4.

Article  CAS  PubMed  Google Scholar 

Merchant SH, VanderJagt T, Lathrop S, Amin MB. Sporadic duodenal bulb gastrin-cell tumors: association with Helicobacter pylori gastritis and long-term use of proton pump inhibitors. Am J Surg Pathol. 2006;30:1581–7.

Article  PubMed  Google Scholar 

Soto-Solís R, Romano-Munive AF, de Anda KS, Barreto-Zuñiga R. Factors related to gastric neuroendocrine tumors. Revista de Gastroenterología de México (English Edition). 2019;84:52–6.

Corsello A, Di Filippo L, Massironi S, et al. Vasostatin-1: a novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. PLoS ONE. 2018. https://doi.org/10.1371/JOURNAL.PONE.0196858.

Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS, Fleisher M, Ramanathan LV, Reidy-Lagunes D, Allen PJ. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. Hpb. 2019;21:612–8.

Trinh VQH, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology. 2020;77:865–76. https://doi.org/10.1111/HIS.14220.

Article  PubMed  Google Scholar 

Rais R, Trikalinos NA, Liu J, Chatterjee D. Enterochromaffin-like cell hyperplasia–associated gastric neuroendocrine tumors may arise in the setting of proton pump inhibitor use: the need for a new clinicopathologic category. Arch Pathol Lab Med. 2022;146:366–71. https://doi.org/10.5858/arpa.2020-0315-OA

Logan K, Shi C. Clinicopathologic features of non–type 1/2 gastric neuroendocrine tumors and their associated mucosal changes. Am J Clin Pathol. 2023;160:130–6.

Baekdal J, Krogh J, Klose M, Holmager P, Langer SW, Oturai P, Kjaer A, Federspiel B, Hilsted L, Rehfeld JF, Knigge U. Limited diagnostic utility of chromogranin A measurements in workup of neuroendocrine tumors. Diagnostics. 2020;10:881.

Jianu CS, Lange OJ, Viset T, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2012;47:64–7. https://doi.org/10.3109/00365521.2011.627444.

Article  CAS  PubMed  Google Scholar 

Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: a review. World J Clin Cases. 2021;9:7973. https://doi.org/10.12998/WJCC.V9.I27.7973.

Article  PubMed  PubMed Central  Google Scholar 

Ahn E, Baek Y, Park JE, et al. Elevated prevalence and treatment of sleep disorders from 2011 to 2020: a nationwide population-based retrospective cohort study in Korea. bmjopen.bmj.com E Ahn, Y Baek, JE Park, S Lee, HJ Jin‏BMJ open, bmjopen.bmj.com. 2024;14. https://doi.org/10.1136/BMJOPEN-2023-075809

Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17:50–63. https://doi.org/10.1038/S41423-019-0339-5.

Article  CAS  PubMed  Google Scholar 

Calvete O, Reyes J, Zuñiga S, Paumard-Hernández B, Fernández V, Bujanda L, Rodriguez-Pinilla MS, Palacios J, Heine-Suñer D, Banka S, Newman WG. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Hum Mol Genet. 2015;24:2914–22.

Calvete O, Varro A, Pritchard DM, et al. A knockin mouse model for human ATP4aR703C mutation identified in familial gastric neuroendocrine tumors recapitulates the premalignant condition of the human disease and suggests new therapeutic strategies. DMM Disease Models and Mechanisms. 2016;9:975–84. https://doi.org/10.1242/DMM.025890/VIDEO-2.

Article  CAS  PubMed  Google Scholar 

Brusselaers N, Kamal H (khodir), Graham D, Engstrand L. Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective. BMJ Open Gastroenterol 2025;12:e001719. https://doi.org/10.1136/BMJGAST-2024-001719

Pan S, Thrift AP, Akhdar G, El-Serag HB. Gastric cancer risk in patients with long-term use of proton pump inhibitors: a systematic review and meta-analysis of observational and interventional studies. Dig Dis Sci. 2023;68:3732–44. https://doi.org/10.1007/S10620-023-08018-9.

Article  CAS  PubMed  Google Scholar 

McCarthy DM. Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids—what is the relationship? Int J Mol Sci. 2020;21:662. https://doi.org/10.3390/IJMS21020662.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen YC, Malfertheiner P, Yu HT, et al. Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterology. 2024;166:605–19. https://doi.org/10.1053/J.GASTRO.2023.12.022.

Article  PubMed  Google Scholar 

Nagao S, Yabuuchi Y, Tanaka K, Morihisa Y, Kobayashi T, Akiyama S, Tanke G, Wada M, Morita S, Inoue S, Hobyung C. Multiple gastric neuroendocrine tumors associated with long-term use of a proton pump inhibitor and a potassium-competitive acid blocker. Intern Med. 2024;63:2001–10.

Patwardhan SS, Basil A, Meunier R, Patel B, Wang X, Cave DR. Is Long-term PPI use associated with the development of gastric neuroendocrine tumors?: 2549. Am J Gastroenterol | ACG. 2016;111:S1290.

Gupta SR, Channen L, Habr F. S5192 Gastric neuroendocrine tumor induced by long-term PPI use. Am J Gastroenterol | ACG. 2024;119:S3251.

Andreasi V, Partelli S, Manzoni M, Muffatti F, Colom